Pathophysiology of acute respiratory distress syndrome. Glucocorticoid receptor-mediated regulation of inflammation and response to prolonged glucocorticoid treatment

Presse Medicale

Volumn 40, Issue 12 PART 2, 2011, Pages

  Umberto Meduri, Gianfranco ^a   Bell, William ^a   Sinclair, Scott ^a   Annane, Djillali ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOTROPIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHYLPREDNISOLONE; NEUROMUSCULAR BLOCKING AGENT; PLACEBO; PROTON PUMP INHIBITOR;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; CONTINUOUS INFUSION; DOWN REGULATION; GASTROINTESTINAL HEMORRHAGE; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INTENSIVE CARE; LENGTH OF STAY; LOADING DRUG DOSE; LUNG GAS EXCHANGE; LUNG RESECTION; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PROGNOSIS; REBOUND INFLAMMATION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SEPSIS; SHORT SURVEY; STRESS ULCER; SYSTEMIC INFLAMMATION; TISSUE REPAIR; WEAKNESS;

EID: 83555162545     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.04.023     Document Type: Short Survey

References (130)

1. Katzenstein A.L., Bloor C.M., Leibow A.A. Diffuse alveolar damage: the role of oxygen, shock and related factors. A review. Am J Pathol 1976, 85(1):209-228.
2. Jantz M.A., Sahn S.A. Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med 1999, 160(4):1079-1100.
3. Murray J.F., Matthay M.A., Luce J.M., Flick M.R. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988, 138(3):720-723.
4. Meduri G.U., Annane D., Chrousos G.P., Marik P.E., Sinclair S.E. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest 2009, 136:1631-1643.
5. Meduri G.U. Clinical review: a paradigm shift: the bidirectional effect of inflammation on bacterial growth. Clinical implications for patients with acute respiratory distress syndrome. Crit Care 2002, 6(1):24-29.
6. Tang B., Craig J., Eslick G., Seppelt I., McLean A. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med 2009, 37:1594-1603.
7. Burton T. Why cheap drugs that appear to halt fatal sepsis go unused 2002, Wall Street Journal.
8. Raoof S., Goulet K., Esan A., Hess D.R., Sessler C.N. Severe hypoxemic respiratory failure: part 2--nonventilatory strategies. Chest 2010, 137(6):1437-1448.
9. Meduri G.U. The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir J 1996, 9(12):2650-2670.
10. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007, 21(2):153-160.
11. Elenkov I.J., Iezzoni D.G., Daly A., Harris A.G., Chrousos G.P. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 2005, 12(5):255-269.
12. Imai Y., Parodo J., Kajikawa O., de Perrot M., Fischer S., Edwards V., et al. Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA 2003, 289(16):2104-2112.
13. Ranieri V.M., Giunta F., Suter P.M., Slutsky A.S. Mechanical ventilation as a mediator of multisystem organ failure in acute respiratory distress syndrome. JAMA 2000, 284(1):43-44.
14. Suffredini A.F., Fantuzzi G., Badolato R., Oppenheim J.J., O'Grady N.P. New insights into the biology of the acute-phase response. J Clin Immunol 1999, 19(4):203-214.
15. Englert J.A., Fink M.P. The multiple-organ dysfunction syndrome and late-phase mortality in sepsis. Curr Infect Dis Rep 2005, 7(5):335-341.
16. Mizgerd J.P. Acute lower respiratory tract infection. N Engl J Med 2008, 358(7):716-727.
17. Rhen T., Cidlowski J.A. Anti-inflammatory action of glucocorticoids. new mechanisms for old drugs. N Engl J Med 2005, 353(16):1711-1723.
18. Hudson L.D., Milberg J.A., Anardi D., Maunder R.J. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995, 151(2 Pt 1):293-301.
19. Steinberg K.P., Hudson L.D. Acute lung injury and acute respiratory distress syndrome. The clinical syndrome. Clin Chest Med 2000, 21(3):401-417. vii.
20. Ashbaugh D.G., Bigelow D.B., Petty T.L., Levine B.E. Acute respiratory distress in adults. Lancet 1967, 2(7511):319-323.
21. Cotran R.S., Kumar V., Robbins S.L. Cellular injury and cellular death. Pathologic basis of disease 1994, W. B. Saunders, Philadelphia, p. 1-34. 5 ed. R.S. Cotran, V. Kumar, S.L. Robbins (Eds.).
22. Meduri G.U., Headley S., Kohler G., Stentz F., Tolley E., Umberger R., et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995, 107(4):1062-1673.
23. Meduri G.U., Muthiah M.P., Carratu P., Eltorky M., Chrousos G.P. Nuclear factor-kappaB- and glucocorticoid receptor alpha- mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation 2005, 12(6):321-338.
24. Roumen R.M., Hendriks T., van der Ven-Jongekrijg J., Nieuwenhuijzen G.A., Sauerwein R.W., van der Meer J.W., et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple-organ failure. Ann Surg 1993, 218(6):769-776.
25. Romaschin A.D., DeMajo W.C., Winton T., D'Costa M., Chang G., Rubin B., et al. Systemic phospholipase A2 and cachectin levels in adult respiratory distress syndrome and multiple-organ failure. Clin Biochem 1992, 25(1):55-60.
26. Groeneveld A.B., Raijmakers P.G., Hack C.E., Thijs L.G. Interleukin 8-related neutrophil elastase and the severity of the adult respiratory distress syndrome. Cytokine 1995, 7(7):746-752.
27. Meduri G.U., Kohler G., Headley S., Tolley E., Stentz F., Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 1995, 108(5):1303-1314.
28. Baughman R.P., Gunther K.L., Rashkin M.C., Keeton D.A., Pattishall E.N. Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. Am J Respir Crit Care Med 1996, 154(1):76-81.
29. Headley A.S., Tolley E., Meduri G.U. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 1997, 111(5):1306-1321.
30. Parsons P.E., Eisner M.D., Thompson B.T., Matthay M.A., Ancukiewicz M., Bernard G.R., et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005, 33(1):1-6. [discussion 230-232].
31. Meduri G.U., Golden E., Freire A.X., Taylor E., Zaman M., Carson S.J., et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007, 131:954-963.
32. Sinclair S.E., Bijoy J., Golden E., Carratu P., Umberger R., Meduri G.U. Interleukin-8 and soluble intercellular adhesion molecule-1 during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment. Minerva Pneumologica 2006, 45(2):93-104.
33. Steinberg K.P., Milberg J.A., Martin T.R., Maunder R.J., Cockrill B.A., Hudson L.D. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994, 150(1):113-122.
34. Gunther K., Baughman R.P., Rashkin M., Pattishall E. Bronchoalveolar lavage results in patients with sepsis-induced adult respiratory distress syndrome: evaluation of mortality and inflammatory response. Amer Rev Respir Dis 1993, 147:A346.
35. Meduri G.U., Tolley E.A., Chinn A., Stentz F., Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998, 158(5 Pt 1):1432-1441.
36. Andrews C.P., Coalson J.J., Smith J.D., Johanson W.G. Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury. Chest 1981, 80(3):254-258.
37. Meduri G.U., Belenchia J.M., Estes R.J., Wunderink R.G., el Torky M., Leeper K.V. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest 1991, 100(4):943-952.
38. Raghavan M., Marik P.E. Stress hyperglycemia and adrenal insufficiency in the critically ill. Semin Respir Crit Care Med 2006, 27(3):274-285.
39. Pustavoitau A., Stevens R.D. Mechanisms of neurologic failure in critical illness. Crit Care Clin 2008, 24(1):1-24. vii.
40. von Kanel R., Hepp U., Kraemer B., Traber R., Keel M., Mica L., et al. Evidence for low-grade systemic pro-inflammatory activity in patients with posttraumatic stress disorder. J Psychiatr Res 2007, 41(9):744-752.
41. El Gamal A., Aleech Y., Umberger R., Meduri G. Sudden cardiac arrest is a leading cause of death in patients with ASCVD admitted to the ICU with acute systemic inflammation. Chest 2008, 134:e587.
42. Bachofen A., Weibel E.R. Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis 1977, 116(4):589-615.
43. Meduri G.U., Eltorky M., Winer-Muram H.T. The fibroproliferative phase of late adult respiratory distress syndrome. Semin Respir Infect 1995, 10(3):154-175.
44. Cordier J.F., Peyrol S., Loire R. Bronchiolitis obliterans organizing pneumonia as a model of inflammatory lung disease. Diseases of the Bronchioles 1994, Raven Press Ltd, New York, p 313-45. G.R. Epler (Ed.).
45. Galon J., Franchimont D., Hiroi N., Frey G., Boettner A., Ehrhart-Bornstein M., et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. Faseb J 2002, 16(1):61-71.
46. Ehrchen J., Steinmuller L., Barczyk K., Tenbrock K., Nacken W., Eisenacher M., et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007, 109(3):1265-1274.
47. Mastorakos G., Bamberger C., Chrousos G.P. Neuroendocrine regulation of the immune process. Cytokines: stress and immunity 1999, FL: CRC Press, Boca Raton, p. 17-37. N.P. Plotnikoff, R.E. Faith, A.J. Murgo, R.A. Good (Eds.).
48. Barnes P.J., Adcock I.M. Glucocorticoids receptors. The lung scientific foundations 1997, Lippincott-Raven, Philadelphis, p. 37-55. 2 ed. R.G. Crystal, J.B. West, E.R. Weibel, P.J. Barnes (Eds.).
49. Baeuerle P.A., Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell 1988, 53(2):211-217.
50. Fan J., Ye R.D., Malik A.B. Transcriptional mechanisms of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2001, 281(5):L1037-L1050.
51. Liu S.F., Malik A.B. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006, 290(4):L622-L645.
52. Marik P.E., Pastores S., Annane D., Meduri G., Sprung C., Arlt W., et al. Clinical practice guidelines for the diagnosis and management of corticosteroid insufficiency in critical illness: Recommendations of an international task force. Crit Care Med 2008, 36:1937-1949.
53. Hermus A.R., Sweep C.G. Cytokines and the hypothalamic-pituitary-adrenal axis. J Steroid Biochem Mol Biol 1990, 37(6):867-871.
54. Perlstein R.S., Whitnall M.H., Abrams J.S., Mougey E.H., Neta R. Synergistic roles of interleukin-6, interleukin-1 and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology 1993, 132(3):946-952.
55. Munck A., Guyre P.M., Holbrook N.J. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984, 5(1):25-44.
56. Meduri G.U., Tolley E.A., Chrousos G.P., Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002, 165(7):983-991.
57. Bohrer H., Qiu F., Zimmermann T., Zhang Y., Jllmer T., Mannel D., et al. Role of NF-kappa B in the mortality of sepsis. J Clin Invest 1997, 100(5):972-985.
58. Paterson R.L., Galley H.F., Dhillon J.K., Webster N.R. Increased nuclear factor-kB activation in critically ill patients who die. Crit Care Med 2000, 28(4):1047-1051.
59. Meduri G.U. An historical review of glucocorticoid treatment in Sepsis. Disease pathophysiology and the design of treatment investigation. Sepsis 1999, 3:21-38.
60. Annane D., Bellissant E., Bollaert P.E., Briegel J., Keh D., Kupfer Y. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev 2004, (1):CD002243.
61. Almawi W.Y., Lipman M.L., Stevens A.C., Zanker B., Hadro E.T., Strom T.B. Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6 and IFN-gamma. J Immunol 1991, 146(10):3523-3527.
62. Kam J.C., Szefler S.J., Surs W., Sher E.R., Leung D.Y. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993, 151(7):3460-3466.
63. Spahn J.D., Szefler S.J., Surs W., Doherty D.E., Nimmagadda S.R., Leung D.Y. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol 1996, 157(6):2654-2659.
64. Farrell R.J., Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003, 178(3):339-346.
65. Meduri G.U., Yates C.R. Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS. Ann N Y Acad Sci 2004, 1024:24-53.
66. Meduri G.U., Headley S., Golden E., Carson S., Umberger R., Kelso T., et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. A randomized controlled trial. JAMA 1998, 280:159-165.
67. Nakamori Y., Ogura H., Koh T., Fujita K., Tanaka H., Sumi Y., et al. The balance between expression of intranuclear NF-kappaB and glucocorticoid receptor in polymorphonuclear leukocytes in SIRS patients. J Trauma 2005, 59(2):308-314. [discussion 14-15].
68. Headley A.S., Meduri G.U., Tolley E., Stentz F. Infections, SIRS and CARS during ARDS and in response to prolonged glucocorticoid treatment (Abstract). Am J Respir Crit Care Med 2000, 161:A378.
69. Keel J.B., Hauser M., Stocker R., Baumann P.C., Speich R. Established acute respiratory distress syndrome: benefit of corticosteroid rescue therapy. Respiration 1998, 65(4):258-264.
70. Varpula T., Pettila V., Rintala E., Takkunen O., Valtonen V. Late steroid therapy in primary acute lung injury. Intensive Care Med 2000, 26(5):526-531.
71. Huh J., Lim C., Jegal Y., Le S., Kim W., Kim D., et al. The effect of steroid therapy in patients with late ARDS. Tuberc Res Dis 2002, 52:376-384.
72. Confalonieri M., Urbino R., Potena A., Piattella M., Parigi P., Puccio G., et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171(3):242-248.
73. Annane D., Sebille V., Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006, 34(1):22-30.
74. Steinberg K.P., Hudson L.D., Goodman R.B., Hough C.L., Lanken P.N., Hyzy R., et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006, 354(16):1671-1684.
75. Meduri G.U., Headley S., Tolley E., Shelby M., Stentz F., Postlethwaite A. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest 1995, 108(5):1315-1325.
76. Fernandes A.B., Zin W.A., Rocco P.R. Corticosteroids in acute respiratory distress syndrome. Braz J Med Biol Res 2005, 38(2):147-159.
77. Headley A.S., Meduri G.U., Tolley E., Belenchia J., Umberger R., Crouse D. Infections and the compensatory anti-inflammatory response during ARDS: Plasma and BAL levels of TGF-b, IL-1ra and sTNFR's. Chest 1997, 112:56S.
78. Meduri G.U., Kanangat S., Stefan J., Tolley E., Schaberg S. Cytokines IL-1beta, IL-6 and TNF-alpha enhance in vitro growth of bacteria. Am J Respir Crit Care Med 1999, 160:961-967.
79. Kanangat S., Meduri G.U., Tolley E.A., Patterson D.R., Meduri C.U., Pak C., et al. Effects of cytokines and endotoxin on the intracellular growth of bacteria. Infect Immun 1999, 67(6):2834-2840.
80. Meduri G.U., Kanangat S., Bronze M.S., Patterson D., Meduri C.U., Pak C., et al. Effects of methylprednisolone on intracellular bacterial growth. Clin Diagn Lab Immunol 2001, 8(6):1156-1163.
81. Meduri G.U., Marik P.E., Chrousos G.P., Pastores S.M., Arlt W., Beishuizen A., et al. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008, 34(1):61-69.
82. Meduri G.U., Mauldin G.L., Wunderink R.G., Leeper K.V., Jones C.B., Tolley E., et al. Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest 1994, 106(1):221-235.
83. Leatherman J.W., Fluegel W.L., David W.S., Davies S.F., Iber C. Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med 1996, 153(5):1686-1690.
84. Egi M., Bellomo R., Stachowski E., French C.J., Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006, 105(2):244-252.
85. Weber-Carstens S., Keh D. Bolus or continuous hydrocortisone: that is the question. Crit Care 2007, 11(1):113.
86. Loisa P., Parviainen I., Tenhunen J., Hovilehto S., Ruokonen E. Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial. Crit Care 2007, 11(1):R21.
87. Hesterberg T.W., Last J.A. Ozone-induced acute pulmonary fibrosis in rats. Prevention of increased rates of collagen synthesis by methylprednisolone. Am Rev Respir Dis 1981, 123(1):47-52.
88. Hakkinen P.J., Schmoyer R.L., Witschi H.P. Potentiation of butylated-hydroxytoluene-induced acute lung damage by oxygen. Effects of prednisolone and indomethacin. Am Rev Respir Dis 1983, 128(4):648-651.
89. Kehrer J.P., Klein-Szanto A.J., Sorensen E.M., Pearlman R., Rosner M.H. Enhanced acute lung damage following corticosteroid treatment. Am Rev Respir Dis 1984, 130(2):256-261.
90. Ashbaugh D.G., Maier R.V. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Diagnosis and treatment. Arch Surg 1985, 120(5):530-535.
91. Hooper R.G., Kearl R.A. Established ARDS treated with a sustained course of adrenocortical steroids. Chest 1990, 97(1):138-143.
92. Briegel J., Jochum M., Gippner-Steppert C., Thiel M. Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001, 12(Suppl. 17):S70-S74.
93. Keh D.B.T., Weber-Cartens S., Schulz C., Ahlers O., Bercker S., Volk H.D., Doecke W.D., Falke K.J., Gerlach H. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003, 167(4):512-520.
94. Nawab Q., Golden E., Confalonieri M., Umberger R., Meduri G. Glucocorticoid treatment in severe community-acquired pneumonia. Am J Respir Crit Care Med 2007, 175:A594.
95. Barber A.E., Coyle S.M., Fischer E., Smith C., van der Poll T., Shires G.T., et al. Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery 1995, 118(2):406-410. [discussion 10-11].
96. Broug-Holub E.KG. Dose- and time-dependent activation of rat alveolar macrophages by glucocorticoids. Clin Exp Immunol 1996, 104(2):332-336.
97. Fantuzzi G., Demitri M.T., Ghezzi P. Differential effect of glucocorticoids on tumour necrosis factor production in mice: up-regulation by early pretreatment with dexamethasone. Clin Exp Immunol 1994, 96(1):166-169.
98. Barber A.E., Coyle S.M., Marano M.A., Fischer E., Calvano S.E., Fong Y., et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993, 150(5):1999-2006.
99. Schaaf M.J., Cidlowski J.A. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 2002, 83(1-5):37-48.
100. Cooper M.S., Stewart P.M. Adrenal insufficiency in critical illness. J Intensive Care Med 2007, 22(6):348-362.
101. Brower G., Matthay M. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome network. N Engl J Med 2000, 342(18):1301-1308.
102. Wiedemann H.P., Wheeler A.P., Bernard G.R., Thompson B.T., Hayden D., deBoisblanc B., et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006, 354(24):2564-2575.
103. Umberger R., Headley A.S., Waters T., Tolley E., Stentz F., Golden E., et al. Cost-effectiveness of methylprednisolone treatment in unreolving ARDS (Abstract). Am J Respir Crit Care Med 2002, 165:A22.
104. Peter J.V., John P., Graham P.L., Moran J.L., George I.A., Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008, 336(7651):1006-1009.
105. Lamontagne F., Briel M., Guyatt G.H., Cook D.J., Bhatnagar N., Meade M. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care 2010, 25(3):420-435.
106. Sessler C.N., Gay P.C. Are corticosteroids useful in late-stage acute respiratory distress syndrome?. Respir Care 2010, 55(1):43-55.
107. Cerfolio R.J., Bryant A.S., Thurber J.S., Bass C.S., Lell W.A., Bartolucci A.A. Intraoperative solumedrol helps prevent postpneumonectomy pulmonary edema. Ann Thorac Surg 2003, 76(4):1029-1033. [discussion 33-35].
108. Lee H.S., Lee J.M., Kim M.S., Kim H.Y., Hwangbo B., Zo J.I. Low-dose steroid therapy at an early phase of postoperative acute respiratory distress syndrome. Ann Thorac Surg 2005, 79(2):405-410.
109. Guyatt G., Gutterman D., Baumann M.H., Addrizzo-Harris D., Hylek E.M., Phillips B., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest 2006, 129(1):174-181.
110. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34(1):17-60.
111. Weigelt J.A., Norcross J.F., Borman K.R., Snyder W.H.D. Early steroid therapy for respiratory failure. Arch Surg 1985, 120(5):536-540.
112. Bernard G.R., Luce J.M., Sprung C.L., Rinaldo J.E., Tate R.M., Sibbald W.J., et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987, 317(25):1565-1570.
113. Meduri G., Marik P., Annane D. Prolonged glucocorticoid treatment in ARDS: evidence supporting effectiveness and safety. Critical Care Medicine 2009, 37:1800-1803.
114. Kaufmann I., Briegel J., Schliephake F., Hoelzl A., Chouker A., Hummel T., et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Med 2008, 34(2):344-349.
115. Sibila O., Luna C., Agustí C., Baquero S., Garcia-Morato J., Rano A., et al. Effects of corticosteroids an animal model of ventilator-associated pneumonia. Proc Am Thorac Soc 2006, 3:A21.
116. Estruch R., Pedrol E., Castells A., Masanes F., Marrades R.M., Urbano-Marquez A. Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward. Scand J Gastroenterol 1991, 26(8):819-826.
117. Ben-Menachem T., Fogel R., Patel R.V., Touchette M., Zarowitz B.J., Hadzijahic N., et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ann Intern Med 1994, 121(8):568-575.
118. Cook D.J., Witt L.G., Cook R.J., Guyatt G.H. Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med 1991, 91(5):519-527.
119. Cook D.J., Fuller H.D., Guyatt G.H., Marshall J.C., Leasa D., Hall R., et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994, 330(6):377-381.
120. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14 1998. Am J Health Syst Pharm 1999; 56(4):347-79.
121. Matsumoto T., Kaibara N., Sugimachi K., Kawarada Y. Pathophysiology and management of acute gastric mucosal hemorrhage. Jpn J Surg 1978, 8(4):261-269.
122. Filaretova L., Podvigina T., Bagaeva T., Bobryshev P., Takeuchi K. Gastroprotective role of glucocorticoid hormones. J Pharmacol Sci 2007, 104(3):195-201.
123. Stevens R.D., Dowdy D.W., Michaels R.K., Mendez-Tellez P.A., Pronovost P.J., Needham D.M. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med 2007, 33(11):1876-1891.
124. Hough C.L., Steinberg K.P., Taylor Thompson B., Rubenfeld G.D., Hudson L.D. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med 2009, 35(1):63-68.
125. De Jonghe B., Bastuji-Garin S., Sharshar T., Outin H., Brochard L. Does ICU-acquired paresis lengthen weaning from mechanical ventilation?. Intensive Care Med 2004, 30(6):1117-1121.
126. Thompson B.T., Ancukiewicz M., Hudson L.D., Steinberg K.P., Bernard G.R. Steroid treatment for persistent ARDS: a word of caution. Crit Care 2007, 11(6):425.
127. Cuthbertson B.H., Sprung C.L., Annane D., Chevret S., Garfield M., Goodman S., et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009, 35(11):1868-1876.
128. Whitted A.D., Stanifer J.W., Dube P., Borkowski B.J., Yusuf J., Komolafe B.O., et al. A dyshomeostasis of electrolytes and trace elements in acute stressor states: impact on the heart. Am J Med Sci 2010, 340(1):48-53.
129. Meduri G.U., Muthiah P., Carratu P., El Torky M. Activation and regulation of systemic inflammation during acute respiratory distress syndrome. Interaction between nuclear factor-kB and glucocorticoid receptors and its effect on the transcription of inflammatory cytokines. Neurol Immunol Modulation 2005, 12(6):321-338.
130. Meduri G.U., Rocco P.R., Annane D., Sinclair S.E. Prolonged glucocorticoid treatment and secondary prevention in acute respiratory distress syndrome. Expert Rev Respir Med 2010, 4(2):201-210.